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Identity 
Other names: JTK14, TIE 
HGNC (Hugo): TIE1 
Location: 1p34.2 
Note 
Receptor tyrosine kinase, member of the TIE family 
(other member: TIE2/TEK). Highly conserved 
sequence across vertebrate species, with greatest amino 
acid homology occurring in the kinase domain. 
DNA/RNA 
Description 
The human TIE1 gene spans 22115 bp, encoding for 23 
exons in forward strand. 
Transcription 
Longest mRNA contains 3882 bp. Alternatively spliced 
forms have been reported, including transcript variant 5 
(EU826590.1) coding for a soluble TIE1 ectodomain 
(Jin et al., 2008). 
 
The genomic (top) and the protein domain structures (below) of human TIE1. Black boxes represent exons with intervening intron 
sequences (lines), light gray boxes represent non-coding sequences of first and last exons. Exon length (black text) and intron length of 
the longest introns (pink) are indicated in nucleotides. The protein domain coding regions of exons are indicated with colours according to 
the TIE1 protein domain structure. SS= signal sequence, Ig= immunoglobulin-like domain, EGF= epidermal growth factor-like domain, 
FN3= fibronectin type-III domain, TM= transmembrane domain, TK= tyrosine kinase domain. Protein domain prediction was performed 
using (SMART). The crystal structure for Tie2 shows the existence of a third Ig-like domain, immediately after the SS (Barton et al., 










Atlas Genet Cytogenet Oncol Haematol. 2012; 16(8)  560 
Protein 
Note 
See figure above. 
Description 
Human TIE1 contains 1138 aa. It belongs to the protein 
kinase superfamily, protein receptor tyrosine kinase 
family, TIE subfamily.  
It contains 3 Ig (immunoglobulin)-like domains (I set 
type), 3 EGF (epidermal growth factor)-like domains, 3 
fibronectin type-III domains, a single transmembrane 
domain and 1 intracellular split tyrosine kinase domain 
(Partanen et al., 1992). 
Expression 
TIE1 is almost exclusively expressed in endothelial 
cells both in human and in mouse. High expression of 
TIE1 mRNA is found in adult lung, heart, and placenta, 
some expression in kidney, whereas muscle, brain, liver 
and pancreas contain less TIE1 mRNA.  
Tie1 mRNA is present widely in fetal tissues starting at 
embryonic day 8,5 (Korhonen et al., 1992).  
Tie1 mRNA is detected in differentiating angioblasts of 
the head mesenchyme, in the splanchnopleure and 
dorsal aorta as well as in migrating endothelial cells of 
the developing heart, in the heart endocardium and in 
the endothelial cells forming the lung vasculature 
(Korhonen et al., 1992).  
TIE1 is also expressed on cultured endothelial cells, 
some haemopoietic progenitor cells, some myeloid 
leukemia cell lines having erythroid and 
megakaryoblastoid characteristics (Batard et al., 1996) 
and in adult acute myelogenous leukemia (Kivivuori et 
al., 2007).  
TIE1 expression is increased in angiogenic endothelial 
cells during wound-healing, in proliferating ovarial 
capillaries during hormone-induced superovulation and
in tumor blood vessels (Korhonen et al., 1992; 
Kaipainen et al., 1994). Tie1 is downregulated in 
endothelial cells by shear stress (Chen-Konak et al., 
2003), but specifically induced in the mouse 
vasculature by disturbed flow in vascular bifurcations 
and branching points along the arteries (Porat et al., 
2004).  
TIE1 along with ANGPT2 and TEK mRNAs were 
strongly expressed in cells of Kaposi's sarcoma tumor 
cells, and cutaneous angiosarcomas, in contrast to the 
focal low-level expression in normal skin biopsies 




Studies of Tie1 gene targeted mice have revealed that 
Tie1 is critical for the development of blood (Puri et al., 
1995) and lymphatic vasculatures (D'Amico et al., 
2010; Qu et al., 2010) after midgestation.  
Tie1 is essential for endothelial cell survival in the 
developing microvasculature undergoing angiogenic 
sprouting, and essentially in all blood vessels in adult 
(Partanen et al., 1996). Tie1-/- embryos die around 
embryonic day 13,5, depending on the background 
(Puri et al., 1995; D'Amico et al., 2010). The Tie1 
deficient or hypomorphic embryos show also signs of 
edema, due to lymphatic defects involving abnormally 
patterned lymph sacs and peripheral lymphatic vessels 
(D'Amico et al., 2010; Qu et al., 2010).  
The molecular function of TIE1 is not completely 
understood, as it does not directly bind the angiopoietin 
growth factors, which are the ligands for TEK (TIE2). 
However, TIE1 tyrosine phosphorylation is induced by 
angiopoietin-1 (Saharinen et al., 2005; Yuan et al., 
2007), most likely in a complex with TEK (Marron et 
al., 2000; Saharinen et al., 2005). Angiopoietins 
activate TEK in a unique manner, which involves the
translocation of TEK to endothelial cell-cell contacts, 
and TIE1 is also present in these complexes (Saharinen 
et al., 2008). Activation of the TIE1 kinase activity 
using chimeric TIE1 receptors was found to result in 
the activation of the Akt pathway (Kontos et al., 200 ). 
The TIE1 ectodomain is proteolytically cleaved, and 
the cleavage is enhanced by PMA, VEGF and TNF-α 
(Yabkowitz et al., 1999). The proteolytic processing of 
TIE1 may regulate TEK activity (Marron et al., 2007).  
The deletion of both Tie1 and Tek results in a more 
severe phenotype than the deletions of either Tie1 or 
Tek alone (Sato et al., 1995; Puri et al., 1999). The 
deletion of both Tie1 and Angpt1 resulted in impaired 
development of the right-hand, but not left-hand sie 
venous system in the mouse embryo (Loughna and 
Sato, 2001). TIE1 has been implicated as a 
proinflammatory gene and its silencing in cultured 
endothelial cells reduced the expression of 
proinflammatory genes (Chan and Sukhatme, 2009), 
while TIE1 overexpression upregulated adhesion 
molecules including VCAM-1, E-selectin and ICAM-1 
(Chan et al., 2008). 
Homology 
H. sapiens: TIE1; M. musculus: Tie1; R. novergicus: 
Tie1; D. rerio: tie1; X. tropicalis: tie1. 
Mutations 
Somatic 
Somatic missense mutations and synonymous 
substitutions in TIE1 have been detected in human 




TIE1 has not been directly shown to be involved in any
human diseases. Most of the information concerning 
Tie1 function has been retrieved from animal models. 
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Gastric cancer 
Note 
TIE1 expression has been detected in gastric 
adenocarcinoma tissues where its expression inversely 
correlated with patients' survival (Lin et al., 1999). 
Atherosclerosis 
Note 
Tie1 is upregulated in emerging atherosclerotic plaques 
and around developing aneurysms (Porat et al., 2004), 
and Tie1+/- mice bred to the ApoE-deficient background 
displayed a 35% reduction in atherosclerosis relative to 
Tie1+/+;Apoe-/- mice (Woo et al., 2011). 
To be noted 
Note 
Recently, ANGPT2, a ligand for TEK, has been 
identified as a promising target for novel anti-
angiogenic tumor therapies, and inhibition of ANGPT2 
has resulted in inhibition of tumor growth, 
angiogenesis, lymphangiogenesis and metastasis in 
preclinical models (Oliner et al., 2004; Brown et al., 
2010; Mazzieri et al., 2011; Holopainen et al., 201). In 
a phase II clinical trial ANGPT1/ANGPT2 dual 
blocking peptibodies in combination with paclitaxel 
prolonged the progression-free survival of the ovarian 
cancer patients (Karlan et al., 2012). In addition, the 
adenoviral delivery of anti-Tek intrabodies impaired 
tumor growth in preclinical models (Popkov et al., 
2005). ANGPT1 appears to mediate vascular 
normalization of the tumor blood vessels during VEGF 
or ANGPT2 blocking anti-angiogenic therapy (Winkler 
et al., 2004; Falcón et al., 2009). Although evidence for 
the function of TIE1 in tumors is lacking, it should be 
noted that via interaction with TEK, TIE1 might be 
involved in tumor angiogenesis and progression. 
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